NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo-DHF trial.

ABSTRACT:

Study objective

This study aimed to determine if variants in NR3C2, which codes the target protein of spironolactone, or CYP11B2, which is involved in aldosterone synthesis, were associated with spironolactone response, focused on the primary end point of diastolic function (E/e'), in Aldosterone Receptor Blockade in Diastolic Heart Failure (Aldo-DHF) participants.

Design

Post-hoc genetic analysis.

Data source

Data and samples were derived from the multi-center, randomized, double-blind, placebo-controlled Aldo-DHF trial.

Patients

Aldo-DHF participants treated with spironolactone (n = 184) or placebo (n = 178) were included.

Intervention

Participants were genotyped for NR3C2 rs5522, NR3C2 rs2070951 and CYP11B2 rs1799998 via pyrosequencing.

Measurement

SUBMITTER: Dumeny L 

PROVIDER: S-EPMC8688239 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature